Venclexta Available From Onco360

ONCO360 CHOSEN FOR HIGHLY SELECT VENCLEXTA™ (VENETOCLAX) PHARMACY NETWORK

ANOTHER LIMITED DISTRIBUTION WIN FOR THE COUNTRY’S LARGEST INDEPENDENT ONCOLOGY PHARMACY

Onco360 announced today that it has been chosen to be part of the highly select pharmacy network for VENCLEXTA.

VENCLEXTA, an oral oncology medication made by AbbVie, Inc., has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a 17p deletion and have been treated with at least one prior therapy.1 According to the American Cancer Society, approximately 18,960 new cases of CLL are diagnosed in the United States each year.

“On behalf of the entire Onco360 organization, we are extremely proud to have been selected to be part of the limited distribution pharmacy network for this highly anticipated new medication,” said Onco360 President and CEO Paul Jardina. “At Onco360, our focus has always been on providing the most comprehensive and compassionate Oncology Pharmacy care possible for cancer patients. Our focus and patient-first approach continues to resonate with patients and their families as well as physicians, pharmaceutical companies and other participants across the continuum of care, and we are thrilled to add VENCLEXTA to our limited distribution portfolio of products.”

VENCLEXTA is immediately available for prescription order from Onco360.  Order Now.

For more information about VENCLEXTA please visit www.VENCLEXTA.com.